Cargando…
Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature
BACKGROUND: High-grade gliomas (HGG) with BRAFV600E mutation represent a unique subset of central nervous system tumors. Targeted therapies including BRAF and MEK inhibitors are now being explored as possible new treatment options. METHODS: We report an 18-year-old female with a grade 3 pleomorphic...
Autores principales: | Arbour, Gabrielle, Ellezam, Benjamin, Weil, Alexander G, Cayrol, Romain, Vanan, Magimairajan Issai, Coltin, Hallie, Larouche, Valérie, Erker, Craig, Jabado, Nada, Perreault, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772816/ https://www.ncbi.nlm.nih.gov/pubmed/36567957 http://dx.doi.org/10.1093/noajnl/vdac174 |
Ejemplares similares
-
Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children
por: Howden, Kaitlyn, et al.
Publicado: (2021) -
Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis
por: Peng, Ling, et al.
Publicado: (2017) -
Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
por: Crowell, Cameron, et al.
Publicado: (2022) -
DIPG in Children – What Can We Learn from the Past?
por: Vanan, Magimairajan Issai, et al.
Publicado: (2015) -
LGG-23. EXCELLENT CLINICAL / RADIOLOGICAL RESPONSE TO BRAF INHIBITION IN A YOUNG CHILD WITH IN-OPERABLE SUPRA-SELLAR PILOCYTIC ASTROCYTOMA
por: Chapman, Stacy, et al.
Publicado: (2020)